Aspergillosis is a fungal infection that primarily affects the respiratory tract. Amphotericin B has broad antifungal activity and is commonly used to treat aspergillosis, a fungal pneumonia that is a common sequela in oiled waterfowl as well as other birds in wildlife rehabilitation. Pharmacokinetic parameters of nebulized amphotericin B in an avian model have been reported, but those of direct intratracheal delivery have yet to be established. The objective of this study was to evaluate if a single 3 mg/kg dose of liposomal amphotericin B delivered intratracheally using a commercial atomizer would achieve plasma and lung tissue concentrations exceeding targeted minimum inhibitory concentrations (MIC) for Aspergillus species in adult mallard ducks (Anas platyrhynchos). Following intratracheal delivery, amphotericin B was present in lung parenchyma at concentrations above the targeted MIC of 1 μg/g for up to 9 days post-administration; however, distribution of the drug was uneven, with the majority of the drug concentrated in one lung lobe. Concentrations in the contralateral lung lobe and the kidneys were above the targeted MIC 1 day after administration but declined exponentially with a 
Introduction
Aspergillosis is a common fungal infection that is an important cause of disease and mortality in birds and mammals. This disease is problematic in both captive and wild waterfowl [1] [2] [3] and is one of the most common etiologies of morbidity and mortality of oiled water birds in rehabilitation centers. 4 In fact, it is considered a limiting factor for the recovery of some avian species affected by oil spills. 5, 6 Oiled birds are compromised due to a number of factors, including loss of body temperature regulation, toxicity of oil, beach stranding, capture, and captive conditions; all these factors render them more susceptible to opportunistic infections like aspergillosis. 5 While the fungus is considered ubiquitous in terrestrial environments, it is not as prevalent in oceanic environments; 7 this lack of previous exposure may contribute to the apparent high susceptibility of seabirds to the pathogen. The majority of avian infections are due to Aspergillus fumigatus, though A. flavus, A. terreus, and A. niger have also been found in affected birds. 8 Aspergillus spp. are primarily opportunistic pathogens, resulting in infection when a bird has been immunocompromised or exposed to overwhelming numbers of fungi. 9 The fungus is typically introduced via inhalation, and most frequently colonizes the lower respiratory tract, although lesions can be found anywhere in the respiratory system, or indeed in the body. [10] [11] [12] Similar to other avian species, aspergillosis most commonly affects the lungs and air sacs of waterfowl. In humans, aspergillosis is a major cause of concern in immunocompromised patients. One study found that 43% of invasive fungal infections in stem cell transplant recipients were due to Aspergillus species, 13 while another found that Aspergillus spp. were the cause of 19% of fungal infections in solid organ transplant recipients. 14 In both birds and humans, aspergillosis can be lethal if untreated or if the particular strain is resistant to available treatments. 11 Amphotericin B has long been used in the treatment of fungal disease and is one of the few fungicidal drugs available. 15 In humans, amphotericin B is frequently selected to treat serious fungal infections in immunocompromised individuals because of its broad-spectrum fungicidal activity. 16 Amphotericin B preferentially targets fungal cell membranes due to its higher affinity for ergosterol over cholesterol. One of amphotericin B's major mechanisms of action is to form a complex with ergosterol in the fungal cell membrane; this complex creates a pore, ion gradients are disrupted, and the ultimate result is cell death. 17 In human medicine, liposomal amphotericin B is preferentially chosen for treating systemic aspergillosis due to the substantial reduction in amphotericin B related renal toxicity. 17, 18 Studies in mouse models of fungal infection have shown the liposomal formulation of amphotericin B to be effective in improving survival and resolving the infection. 19 Aerosol studies using rodent models and specifically targeting the respiratory tract have also administered liposomal amphotericin B using a nebulizer. 20, 21 In contrast, the pharmacokinetics and clinical use of liposomal amphotericin B in avian species have not been extensively investigated.
In situations in which birds are considered to be immunocompromised due to physiological or psychological stress, antifungal drugs are typically administered for aspergillosis prophylaxis. 22 Amphotericin B administration routes for birds have included intravenous or local respiratory tract administration, typically by catheter or nebulization. Long-term, repeated intravenous administration is not feasible in birds due to the difficulty in maintaining vascular access. Furthermore, a study in birds using aerosolized fluorescent microspheres found that nebulization required a clinically impractical time of 2 h for deposition of the microspheres to be visible in the air sac membranes. 23 Positive pressure ventilation has been shown to be effective at introducing fluorescent microspheres into the air sacs, 24 but it is not a practical administration method in scenarios with large numbers of potentially affected animals, such as oil spill responses, when thousands of birds may require care. Recent work using a quail model did demonstrate that nebulization over 30 min with a nanoparticulate itraconazole suspension was able to achieve drug concentrations above reported minimum inhibitory concentrations (MICs) for Aspergillus species, and this method of delivery resulted in a relatively long terminal half-life for lung tissue. 25 To the authors' knowledge, a scientifically established method of direct intratracheal drug delivery for birds has not been published. When compared to nebulization, the advantages of direct intratracheal administration include a reduction in drug volume needed for treating large populations of birds (such as in a rehabilitation setting), rapid delivery of the drug to the pulmonary parenchyma upon intake into a rehabilitation facility and an efficient method for delivering small volumes of medicated fluid homogeneously to the respiratory tract. A better understanding of the pharmacokinetics of intratracheally delivered amphotericin B in birds is the first step to developing prophylactic and therapeutic protocols for avian aspergillosis. The objective of this study was to evaluate whether a single 3 mg/kg dose of liposomal amphotericin B suspension delivered intratracheally, using a commercial atomizer, would achieve plasma and lung tissue concentrations exceeding targeted MIC for Aspergillus species in adult mallard ducks. While mallard ducks are generally considered more disease resilient compared to other seabirds, 5, 11 they are susceptible to aspergillosis and were used here as an avian model for this study. For the first trial, birds were randomly assigned to either the histology or the tissue concentration group, then further randomly distributed into control and treatment groups (Fig. 1) . Ducks in the treatment group were intratracheally dosed once (3 mg/kg) with liposomal amphotericin B suspension (5 mg/ml; AmBisome, Astellas, Northbrook, IL) using a commercial atomizer (Penn-Century Microsprayer R Aerosolizer model IA-1B, Penn-Century Inc., Wyndmoor, PA). The dose (3 mg/kg) was based on empirical clinical experience for the non-liposomal formulation of amphotericin B. The same atomizer was used for intratracheal delivery of 0.9% sodium chloride in the control group. The same person administered all the doses. The ducks were manually restrained, and the atomizer was directly inserted into the glottis. With the goal of drug delivery at the level of the carina, the atomizer was gently introduced into the trachea until resistance was encountered and then was proximally retracted by a few millimeters prior to drug delivery. On average this procedure (positioning animal and drug delivery) took approximately 40 seconds. After 24 h, 3 d, 4 d, 6 d, 7 d, or 9 d post-treatment, blood samples were drawn (n = 6 per time point) using jugular venipuncture, deposited into lithium heparin blood tubes, centrifuged, and the plasma was decanted and stored at 4
Methods

Animal subjects
• C. After being euthanized with an intravenous overdose of pentobarbital, necropsies were performed and lung (left and right sides), kidneys, and liver were removed for histology and drug analysis. Tissues from ducks assigned to the histology group were collected and immersed in 10% neutral buffered formalin for fixation. Tissues collected for quantitative analysis of amphotericin B concentration were homogenized with dry ice by placing frozen tissues in a commercial blender (Waring Blender) with an approximately equal amount of dry ice and blended to a powder consistency. The dry ice was allowed to sublime, then the samples were stored at −80
For the second trial, the nine ducks were divided into three treatment groups (Fig. 1) . The same atomizer was used, but its position inside the trachea was altered in each of the three treatment groups. The goal for treatment group 1 was to centralize the atomizer in the trachea by placing it in the lumen of an endotracheal tube. For treatment group 2, the aim was to manually move the atomizer from side to side to achieve an equal drug distribution. Treatment group 3 was treated in a manner aimed at equalizing drug distribution by forcing the atomizer first to one side and then the other. For all three treatment groups of trial 2 ducks were dosed intratracheally (3 mg/kg) with liposomal amphotericin B 5 min after 0.1 ml of 2% viscous lidocaine was applied to the glottis. In the first treatment group, ducks were intubated with a 3.0 mm cuffed endotracheal tube that was inserted into the trachea 14 cm from the glottis with the cuff deflated. The atomizer was then placed inside the endotracheal tube with the tip of the atomizer extending 2 cm beyond the distal end of the endotracheal tube. In the second treatment group, the ducks were again intubated, but the atomizer was placed in the trachea 7 cm from the glottis and fanned laterally from left to right as the drug was administered. In the third treatment group, the atomizer was attached to the outside of a 10 French red rubber tube with Micropore TM tape (3 M, St. Paul, MN). The duck was intubated with the tube with the atomizer positioned on the right side of the trachea. Half of the dose was delivered, and then the duck was extubated and reintubated with the atomizer on the left side of the trachea and the second half of the dose delivered. All the ducks in trial 2 were humanely euthanized at 24 hours after exposure, and lung, liver, kidney, and muscle were harvested and stored at −70 • C until analysis.
Tissue and plasma sample analysis
For trial 1, homogenized tissue samples (250 mg) were mixed with 50 μl internal standard (50 μg/ml natamycin in methanol) and 2 ml extraction solution (55:35:10 ethanol (95%):water:methanol). Samples were incubated in the dark for 1-2 h, vortexed every 15 min, then centrifuged for 10 min at 2000 × g before being transferred to an autosampler vial for analysis. All samples were analyzed in triplicate (three samples per tissue per duck), and quality control samples spiked at 0, 0.1, 0.5, and 1.0 μg/g were included with each sample set. Amphotericin B tissue concentrations were determined using a UPLC-MS/MS system consisting of a Waters Aquity UPLC, a Thermo TSQ Discovery Max MS/MS (with heated electrospray ionization source), and a BEH C18 1.7 μm 2.1 × 50 mm column (Waters, Milford, MA). Flow rate on the UPLC was 0.25 ml/min isocratic 65:35 0.02 M ammonium acetate:acetonitrile pH adjusted to 4.0 with formic acid, with a column temperature of 35
• C and a sample tem- • C. Sheath gas was 40 psi, ion sweep gas was 0, and auxiliary gas was 10. Collision pressure was 1.0. Collision energy was 10 for natamycin, and 17 for amphotericin B. An external standard curve (0.05-10.0 ppm) was prepared in the extraction solution and had an R 2 of 0.9949. Quality control (QC) samples were also analyzed in triplicate with each sample set. For intra-assay variability, the relative standard deviation (RSD) for the replicates at each QC level was calculated (average/standard deviation × 100). The average of these RSDs was the intraassay variability. For inter-assay variability, the RSD for all of the QCs at each level over all of the runs was calculated. The average of these was the inter-assay variability. Limit of detection (LOD) was calculated as the average baseline at the retention time of the amphotericin B peak plus 3 times the standard deviation of that average (average + 3 × SD). Limit of quantification (LOQ) was calculated as the average baseline at the retention time of the amphotericin B peak plus 10 times the standard deviation of that average (average + 10 × SD). Plasma samples were extracted by addition of 3-nitrophenol as an internal standard and protein precipitation with methanol and centrifugation. Extracted samples were analyzed isocratically on an Alliance 2695 HPLC system (Waters Corp) with UV detection at 406 nm. The column was a Zorbax SB-C8, 4.6 × 150 mm. Mobile phase was 50:50 0.05 M sodium acetate:acetonitrile at a flow rate of 1.0 ml/min. The standard curve range was 0.1 to 20 μg/ml, and the recovery was 95%. Variability, as measured by relative standard deviation, was 15.7%.
For trial 2, tissues were extracted with 1:5 tissue (g) to methanol (ml) and 10 ul/250 mg tissue of internal standard (50 ug/ml natamycin) was added. Tissues were then homogenized using a commercial homogenizer (Polytron PT 10-35 Blade-type Homogenizer, Brinkmann Inc., Riverview, FL). Samples were centrifuged for 5 min at 10,000 × g before being transferred to autosampler vials. As in trial 1, samples were analyzed in triplicate using the same UPLC-MS/MS methods with sample temperature changed to 25
• C, injection volume decreased to 5 ul, and the mobile phase shifted to 60:40 0.02 M ammonium acetate:acetonitrile. 
Histopathology
Tissues from euthanized birds in trial 1 were fixed in 10% buffered formalin, then tissues of lung, trachea, and bronchi in the region of the carina, heart, kidney, and liver were embedded in paraffin, sectioned at 5 μm, and stained with hematoxylin and eosin for evaluation by light microscopy. Criteria for histopathologic evaluation of tissues were established (Table 1) and pathological changes were graded on a scale of 0-4, where 0 = not present, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe. Scores were calculated by totaling the grades from all criteria in each tissue for all ducks in a group (Control, 1 day, 4 days, and 7 days postdosing with amphotericin) and then averaging the score per animal for each tissue.
Data analysis
Pharmacokinetic parameters were estimated from the time versus concentration data and a commercial software program (Phoenix R WinNonlin R Certara TM Princeton, NJ).
The observed maximum plasma concentration (C max(obs) ) was determined directly from the time versus concentration data. A sparse data approach was utilized to estimate the area under the curve from time 0 to the last quantifiable measurement (AUC 0-last ) using the linear trapezoidal rule. Amphotericin B tissue concentrations from trial 1 (right lung, left lung, and kidney) were ln-transformed, and their relationship to time explored by linear regression analysis using XLSTAT R (Addinsoft, NY, NY), a statistical plugin for Excel R (Microsoft Corporation, Redmond, WA). If the regression analysis yielded a significant decline in concentrations over time, the slope of the line was used to calculate an elimination half-life using the following equation:
The target MIC was 1 μg/ml, selected based on a study that reported MIC for amphotericin B for Aspergillus isolates from falcons.
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Results
Assay parameters
The limit of detection (LOD) was 0.04 and 0.06 μg/g for lung and kidney, respectively. The limit of quantification (LOQ) was 0.08 and 0.15 μg/g. Average recovery was 100.1% for lung and 96.7% for kidney. Inter-assay variability, as measured by relative standard deviation, was 7.1% and 6.3%, respectively, and intra-assay variability was 4.8% and 3.6%.
Amphotericin B tissue and plasma concentrations
In trial 1, concentrations of amphotericin B were analyzed for the left and right lung lobes separately, except for the 9-day treatment group. The most notable result was that amphotericin B was lateralized to the left lung lobe in the majority of subjects. The mean ± SD left lung tissue concentration 24 h post-treatment was 42.7 ± 31.6 μg/g of tissue, while the mean right lung tissue concentration 24 h post-treatment was 19.9 ± 45.3 μg/g of tissue (Table 2 ). For ducks sampled on day 1 post-treatment, the majority (n = 5) had right lung concentrations below 2.0 μg/g of tissue, with the exception of one animal (112.5 μg/g of tissue). Amphotericin B concentrations in the left lung did not decrease significantly over 8 days (P = .6; Fig. 2A ), whereas the For treatment groups with 2 data points or less, individual values are listed instead of the mean ± SD. * Treatment group 1: Treatment goal was to centralize the atomizer in the trachea by placing it in the lumen of an endotracheal tube.
Treatment group 2: Treatment goal was to manually move the atomizer from side to side to achieve an equal drug distribution. Treatment group 3: Treatment goal was to equalize drug distribution by securing the atomizer first to one side of the trachea and then the other during drug administration.
ln-transformed concentrations in the right lung declined linearly over 8 days (P < .01; Fig. 2B ). By day 9 post-treatment, the combined right and left lung average was 8.07 ± 6.77 (range = 2.3-18.8) μg/g tissue. The kidney concentrations were lower than lung concentrations (Table 2 ) and also declined exponentially (linearly when ln-transformed) over 9 days (P < .01; Fig. 2C ). Mean kidney tissue concentration after 24 h was 1.51 ± 0.70 μg/g of tissue. The half-lives (reported as mean with upper and lower 95% confidence limits) for right lung and kidney amphotericin B concentrations were 1.2 (0.9-1.8) and 2.1 (1.6-3.1) days, respectively. The C max(obs) values were 108.8, 112.5, and 2.7 for left lung, right lung, and kidney, respectively. Plasma concentrations of amphotericin B were found to be below the targeted MIC at all time-points (Table 2) . On day 1 post-treatment only three ducks had measurable drug concentrations (0.16, 0.38, and 0.50 μg/ml) and on day 3 post-treatment there were only two ducks with measurable concentrations (0.19 μg/ml for both ducks). Over time, the mean plasma concentrations of amphotericin B decreased and were below the LOD at four time-points post-treatment (4, 6, 7, and 9 d post-treatment). These data were not analyzed by linear regression since there were only data at two time-points.
In trial two, concentrations of amphotericin B were similarly lateralized to one lung lobe for treatment groups 1 and 3 (Table 3 ). In contrast to trial 1, amphotericin B was lateralized to the right lung lobe. For the majority of the birds (6/9), drug lateralization occurred and for 1 bird, the amount of drug measured in both lungs was minimal. For treatment group 2 (fanning action for drug delivery), two of the four birds resulted in bilateral drug distribution in the lungs. Treatment groups 1 and 2 had higher renal drug concentrations compared to treatment group 3 and the ducks in trial 1. Liver concentrations in treatment group 2 were markedly higher than treatment 1 or 3. Muscle concentrations for all three groups were below 0.5 μg/g for all subjects.
Clinical and post-mortem observations
Following treatment, no differences in clinical signs were noted between animals in the control and treatment groups. No significant changes in overall subject weights were noted; in trial 1 the initial weight average was 1.06 ± 0.09 kg and the ending weight average was 1.05 ± 0.08 kg, and for trial 2 the initial weight average was 1.15 ± 0.11 kg and the ending weight average was 1.13 ± 0.11 kg. At necropsy, no gross differences in the respiratory tract were observed between the control and treatment groups.
Histology
For the birds in trial 1, pathologic changes were present in the trachea, bronchi, and lungs, and were similar across treatment and control groups (Table 4) . No microscopic lesions in the kidneys, liver, or heart were found that were attributed solely to amphotericin B treatment.
Discussion
Following a single intratracheal administration of liposomal amphotericin B at 3 mg/kg using a commercial atomizer, drug concentrations were above the target MIC of 1 μg/ml in lung tissue from mallard ducks, with the majority of the drug concentrated in one of the lung lobes (mostly left or right for trials 1 and 2, respectively). Drug concentrations in pulmonary parenchyma reached above the targeted MIC for avian isolates of Aspergillus species of 1 μg/ml 26 and decreased over time after drug administration. These results indicated that the atomizer delivered measurable and sustained amphotericin B concentrations to the lung parenchyma of mallard ducks; however, distribution of the drug was strongly lateralized. Although the lung tissue concentrations were above the targeted MIC, there was a difference in the concentration Table 4 . Histologic scores for pathologic changes observed in the trachea, bronchi, and lungs from control (n = 4) and amphotericin B exposed (n = 18) mallard ducks given a single intratracheal dose of liposomal amphotericin B at 3 mg/kg using a commercial atomizer (Trial 1). Criteria for histopathologic evaluation was established for each tissue/organ. Grading scale was 0 = not present, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe for trachea, bronchi, and lung. Number of parameters evaluated per anatomic section were trachea (4), bronchi (6) and lung (6) . In the trachea and bronchi categories, one of the parameters was graded on a scale of 0 (not present) and 1 (present) instead of the 0-4 scale.
of amphotericin B in the right lung (trial 1) compared to that in the left lung, with the exception of one duck at 24 h. The commercial atomizer is not curved but is very long and narrow in diameter and might have inadvertently been distally directed to one side of the trachea, thereby contributing to the disparity between amphotericin B concentrations in the left and right lung parenchyma. To the authors' knowledge, there are no reports that the trachea of a mallard duck bifurcates unevenly at the carina. Uneven bifurcation was not observed on gross examination, which is consistent with reports of the structural anatomy of the respiratory tract in mallard ducks. 27 However, one study did find a tendency for the left bronchial cartilage rings to be slightly larger than those of the right bronchi in female ducks. 28 The one instance where the right lung was found to have a higher amphotericin B concentration than the left lung could have resulted from the drug being directed down the right bronchus instead of the left, or from an inadvertent mislabeling of right and left lung samples. For the renal and right lung tissues in trial 1, drug concentrations exponentially decreased over time with estimated elimination half-lives for the renal and right pulmonary tissues that were substantially longer in this study compared to half-lives reported for other species. [29] [30] [31] [32] This could be attributable to "flip-flop" kinetics, where the absorption is prolonged and dominates over the elimination of the drug. 33 In contrast, drug concentrations in the left lung were sustained at high concentrations for long periods of time, possibly because only a very small proportion of the dose was absorbed systemically and therefore cleared from the site of deposition. Differences between drug depletion in tissues is most likely attributed to wide concentration ranges. Tissues with low drug concentrations had noticeable declines over the sampling time period. In contrast, left lung samples from trial 1 had high drug concentrations and decreasing drug concentrations were not readily observed during the sampling period since mucociliary clearance and phagocytosis are not first order processes.
Trial one amphotericin B concentrations in the kidneys were detectable, but low, and below the targeted MIC at every time point except 24 h post-treatment. In contrast, despite the same administered dose (3 mg/kg), average renal amphotericin B concentrations for trial 2, Groups 1 and 2 ducks were much higher compared to trial 1. The reasons for this difference may have been the overall greater drug concentrations delivered to the pulmonary parenchyma in trial 2, groups 1 and 2 ducks compared to trial 1 ducks.
Kidney concentrations were of particular interest since amphotericin B has been reported to be nephrotoxic in birds. 15 Nephrotoxicity is the most severe adverse effect associated with amphotericin B in humans. Histopathologic renal changes reported with amphotericin B administration include thickening of glomerular capillary loops, cortical tubular atrophy, cortical and medullary tubular epithelial necrosis, and intratubular calcification. [34] [35] [36] With nonliposomal formulations of amphotericin B, the dosage must be low enough to prevent renal damage secondary to drug administration. This may result in plasma concentrations below the necessary concentrations for successful antifungal therapy. 16 The low amphotericin B kidney concentrations following dosing suggest that there was minimal systemic distribution of the drug post-administration, and that the majority of the drug remained at the delivery site. In addition, plasma concentrations of amphotericin B were below targeted MIC and decreased to nondetectable concentrations by 4 days post-treatment, further supporting the idea that the drug remained primarily in the target organ and systemic uptake was minimal. These low systemic and renal concentrations may also be partially attributed to pulmonary macrophage uptake of liposomal amphotericin B helping to maintain drug concentrations at the delivery site. 37 There were no signs of drug-associated damage on histopathologic examination of renal, hepatic, or cardiac tissue samples. For trial 1, lesions in the airways and lungs were not significantly different between treatment and control groups. Given the nature of pathologic lesions, environmental conditions (where the birds were raised and housed prior to study enrollment) were suspected to be responsible versus mechanical injury (especially for the tracheas). Such lesions could also be attributable to environmental conditions, such as dry air and an enclosed space. The absence of any histological evidence of renal damage supports the conclusion that intratracheal administration of liposomal amphotericin B using an atomizer confined the drug to the target organ of lung parenchyma, without any significant systemic absorption. The greatly reduced risk of renal toxicity when administering the liposomal formulation of this drug intratracheally, compared to the nonliposomal formulation administered systemically, combined with its broad antifungal spectrum, together make liposomal amphotericin B a highly attractive choice for prophylactic and therapeutic treatment of birds with fungal infections.
Trial 2 of this study aimed to resolve the marked lateralization of the drug observed in trial one. Unfortunately, none of the methods were uniformly successful. Trial 2 showed lateralization predominately to the right lung, while trial 1 showed lateralization predominately to the left lung. The individuals administering the drug for both trials were right handed and the method for restraining the ducks was identical. Treatment group 2 was the only one that had some success, with two of the four subjects achieving bilateral distribution. Both of these birds were female, while the two birds that had uneven drug distribution were male. It is possible that the difference in tracheal length between the males and females played a role; males tend to be larger than females, and the atomizer may not have extended far enough into the trachea for the males.
Along with atomizer length and orientation, atomizer drug delivery to the lungs depends on both the drug atomization process and delivery instrument design. The liquid drug formulation requires atomization into micron-sized droplets in order to be able to track the airflow into the lungs. The droplet size distribution helps determine if even dispersion occurs in the lung. If the liquid droplets formed in these trials were too large or if droplets were formed with highly variable diameters, the characteristics of droplet and air flow interaction in the lungs may have been altered 38 and could result in uneven droplet distribution. The atomizer itself determines the droplet size and dispersion with the design of the needle tip and the amount of force used to drive the syringe motion to expel the liquid. If the amount of pressure generated within the 1 ml syringe used did not meet the required atomization and dispersion forces needed to create micron sized drug droplets, uneven distribution may have resulted. Aside from the orientation of the atomizer during administration, these are a few of the basic parameters that may have had an effect on the drug lateralization seen in the trials.
To evaluate reasons why a commercial atomizer results in asymmetric drug delivery, Ruvalcaba et al. 39 systematically tested drug delivery using a 3D printed trachea model wall. The goal of the study was to determine factors that could affect the creation of the aerosol droplet size, spray cone angle, and droplet velocity. Ruvalcaba et al. 39 developed three experimental conditions using a geometrically equivalent model trachea to: (1) qualitatively evaluate the spray dynamics in a confined space, (2) quantitatively analyze dispersion as compared to animal experiments, and (3) quantitatively control atomizer location in the model trachea. Their study found that spray generated from the atomizer coalesced at a 3D printed trachea model wall rather than being carried downstream, resulting in gravity governed dispersion of the larger droplets, created by coalescence. Further, aerosol generation was highly dependent on the distance proximal to the carina as well as the centering of the atomizer in the model trachea. Based on the results from Ruvalcaba et al., 39 it is possible that the unilateral drug delivery seen with the ducks in our study was due to an inability to center the atomizer in the tracheal lumen and the positioning relative to the carina that resulted in the liquid form of the drug coalescing on one side of the trachea mucosa. Limitations of this study included a relatively small sample size. In addition, only healthy mallard ducks were included, whereas in a clinical setting immunocompromised patients would be infected. Therefore, future considerations would be to evaluate drug distribution and treatment efficacy using immunosuppressed birds. While these results are promising in terms of high lung concentrations achieved for a prolonged duration, the problem of drug lateralization must be resolved before this technique can be recommended for clinical use and further investigation is needed. Liposomal amphotericin B treatment toxicity in birds should also be evaluated using a low to high range of dosing regimens and assessing avian hepatic and renal biochemical parameters combined with histopathology.
The intended application of this technique is in scenarios with large numbers of birds suspected of or at high risk for immunosuppression, such as a wildlife rehabilitation center accepting seabirds and waterfowl contaminated by an oil spill. In such situations, aspergillosis is of great concern, as it is primarily an opportunistic infection. These study results support a possible treatment option that minimizes bird handling on admission to a wildlife rehabilitation facility where an oiled bird could prophylactically and safely be given a single intratracheal dose of amphotericin B, treated at appropriate intervals while in rehabilitation, and then administered a final dose upon release.
